

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>Adalimumab</b>
Brand Name	Humira®
Dosage Form(s)	40 mg in 0.8 mL solution for subcutaneous injection
Manufacturer	AbbVie Corporation
<b>Submission Type</b>	<b>Ministry initiated review</b>
Use Reviewed	Hidradenitis Suppurativa (HS)
Common Drug Review (CDR)	Yes, CDR previous recommendation is: <b>to Reimburse with clinical criteria and/or conditions.</b> Visit the CDR website for more details: <a href="http://www.cadth.ca/sites/default/files/cdr/complete/SR0455_complete_Humira-HS_May-24-16_e.pdf">www.cadth.ca/sites/default/files/cdr/complete/SR0455_complete_Humira-HS_May-24-16_e.pdf</a>
Provincial Review	Adalimumab was initially reviewed by the Drug Benefit Council (DBC) on June 6, 2016. This resubmission was internally reviewed because it did not include any new clinical data. For more details on the DBC previous review, please visit the Ministry website: <a href="http://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/decisions/adalimumab-humira-3440-dds.pdf">www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/decisions/adalimumab-humira-3440-dds.pdf</a>
<b>Drug Coverage Decision</b>	<b>Limited Coverage Benefit. Access the adalimumab criteria from</b> <a href="http://www.gov.bc.ca/pharmacarespecialauthority">www.gov.bc.ca/pharmacarespecialauthority</a>
Date	March 6, 2018
Reason(s)	<b>This decision supersedes the Ministry decision of April 18, 2017.</b> <ul style="list-style-type: none"> <li>The Ministry decided to join an agreement reached between the pan-Canadian Pharmaceutical Alliance (pCPA) and AbbVie Corporation. As a result, pricing concerns raised in the initial DBC recommendation have been addressed.</li> </ul>
Other Information	None

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.